Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2021 - 2025)

Monte Rosa Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $8.0 million for Q1 2025.

• In Q1 2025, Accumulated Expenses rose 126.76% year-over-year to $8.0 million; the TTM figure through Mar 2025 stood at $8.0 million (up 126.76% YoY), while the FY2024 annual figure was $7.2 million, up 35.14% from the prior year.
• Accumulated Expenses was $8.0 million for Q1 2025 at Monte Rosa Therapeutics, up from $7.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.0 million in Q1 2025 to a low of $3.2 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $5.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses fell 20.28% in 2022, then jumped 126.76% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $4.9 million in 2021, then declined by 20.28% to $3.9 million in 2022, then soared by 35.57% to $5.3 million in 2023, then jumped by 35.14% to $7.2 million in 2024, then climbed by 11.29% to $8.0 million in 2025.
• The last three Accumulated Expenses figures came in at $8.0 million (Q1 2025), $7.2 million (Q4 2024), and $6.7 million (Q3 2024), per Business Quant data.